12.6 Adverse events monitoring

exp date isn't null, but text field is

Individuals who receive treatment for LTBI do not have active disease, and therefore, it is mandatory to minimize risks during treatment. Drug-specific adverse reactions can occur with isoniazid (asymptomatic elevation of serum liver enzyme concentrations, peripheral neuropathy and hepatotoxicity); rifampicin and rifapentine (cutaneous reactions, hypersensitivity reactions, gastrointestinal intolerance and hepatotoxicity). While most adverse drug reactions are minor and occur rarely, special attention should given to prevention of drug induced hepatotoxicity.

Baseline laboratory testing should be undertaken for individuals with the following risk cofactors: history of liver disease, regular use of alcohol, chronic liver disease, HIV infection and pregnancy or the immediate postpartum period (i.e., within three months of delivery). For individuals with abnormal baseline test results, routine periodic laboratory testing should be carried out.